Characterizing the evolutionary history of a gene's expression profile is a critical component for understanding the relationship between genotype, expression, and phenotype.
One Sentence Summary:
We demonstrate the power of a stochastic model for quantifying selective pressure on expression and estimating evolutionary distributions of optimal gene expression.
Comparative genomics has identified and annotated functional genetic elements by their evolutionary patterns across species (1) (2) (3) (4) (5) (6) . Current comparative studies focus primarily on analysis of genomic sequences, using a well-established theoretical framework developed in the 1960s based on observations that neutral sequence diverges linearly across time (7) (8) (9) (10) (11) . These models allow for detection of sequence elements that evolve slower (e.g., due to purifying selection) or faster (e.g., due to positive selection or relaxed selective constraints) than expected under the null model of neutral evolution.
It has long been accepted that divergence of gene regulation, manifested by phenotypic changes in gene expression, also plays a key role in evolution (12) (13) (14) (15) (16) (17) . An evolutionary analysis of gene expression should help interpret gene function and evolutionary processes in ways that cannot be addressed by sequence alone: signatures of purifying selection on a gene's expression across tissues could reveal the context in which it plays the most important role; the strength of evolutionary constraint on a gene's expression could help interpret expression data from clinical samples; and genes whose expression is under directional (positive) selection can help assess the basis of lineage-and species-specific phenotypes.
Though theoretical models of expression evolution have been proposed (18) (19) (20) (21) , most studies have not applied these models to address functional questions. Initial studies on an evolutionary model for gene expression have also been hampered by small datasets, leading to conflicting results. Indeed, some studies concluded that expression is diverging at a linear rate across time, suggestive of widespread neutral evolution (22) (23) (24) (25) , whereas others determined that the evolutionary rate is constant, suggestive of strong purifying selection (20, (26) (27) (28) (29) .
To systematically explore expression evolution, we compiled a well-sampled dataset across the mammalian phylogeny, spanning 17 species and 7 different tissues (brain, heart, muscle, lung, kidney, liver, testis) ( Fig. 1A, table S1 ). The dataset combines published data for 12 species (28, (30) (31) (32) (33) (34) with data for five additional species we newly collected here ( Fig. 1A, asterisk, SOM) to improve phylogenetic coverage. We focused on the 10,899 annotated mammalian one-to-one orthologs (35) . As expected (36) , expression profiles first cluster by tissue and then by species ( fig. S1) , and their hierarchical clustering closely matches the phylogenetic tree ( fig. S2 ).
On average, pairwise expression differences relative to a specific species (SOM) do not increase linearly with evolutionary time (Fig. 1B, fig. S3,4) , but instead plateau. For example, when comparing to human profiles, differences plateau beyond the primate lineage (43.2 million years) (37) (Fig. 1B, fig. S3 ). This relationship is observed in each of the five tissues for which we have expression data for all primates (brain, heart, kidney, liver, testis) ( fig. S3) , and regardless of reference species ( fig. S4) , albeit with varying rates.
The observed pattern of expression divergence is accurately modelled by an Ornstein-Uhlenbeck (OU) process (average mean squared error across tissues = 0.002) (Fig. 1C, D) . This stochastic process was initially proposed as a model for phenotypic evolution by Hansen (19) and has more recently gained traction for modelling expression evolution across Drosophila, suggesting that it may be generalizable across the animal kingdom (20, 21, 38) . Thus far, OU models have primarily been employed for theoretical inferences about fitness gains and selective effects of evolving expression levels, with one previous limited application for detecting selection on expression across a smaller mammalian phylogeny of 9 species (28) . Here, we extend previous work with a better powered phylogeny to demonstrate how to apply the OU model to yield interpretable answers to functional questions about expression evolution, disease gene discovery, and lineage-specific adaptations.
In the context of expression, the OU process (Fig. 1C) is a modification of a random walk, describing the change in expression (dX t ) across time (dt) by dX t = σdB t + α(θ -X t ) dt, where dB t denotes a Brownian motion process. The model elegantly quantifies the contribution of both drift and selective pressure for any given gene: (1) drift is modeled by Brownian motion with a rate σ (Fig. 1C , top), while (2) the strength of selective pressure driving expression back to an optimal expression level θ is parameterized by α (Fig. 1C, bottom) . The OU process incorporates time information and fully accounts for phylogenetic relationships, thus allowing us to fit individual evolutionary expression trajectories. At longer time scales, the interplay between the rate of drift (σ) and the strength of selection (ɑ) reaches equilibrium and, as time increases to infinity, constrains expression X t to a stable, normal distribution, with a mean, θ, and variance, σ 2 / 2ɑ ( Fig. 1D) .
We applied the OU model to yield biologically interpretable results to evolutionary questions about gene expression. First, for each tissue separately, we estimate from our data, the asymptotic distribution of optimal expression for genes under stabilizing selection. We then use this distribution's OU variance (which we term 'evolutionary variance') to characterize how constrained a gene's expression is in each tissue. Second, we compare the observed gene expression in an individual patient with disease to the optimal level from the model, in order to detect potentially deleterious expression levels and use those to nominate causal disease genes.
Third, we use an extension of the OU model (39) to account for the existence of multiple distributions of optimal expression within a phylogeny and apply them to identify genes undergoing adaptive evolution within subclades. We describe each of these applications in turn.
To test whether a gene is under stabilizing selection, we used a likelihood ratio test to compare the fit with no selection (α = 0; Brownian motion only; Fig. 2A , top) to one with stabilizing selection (α > 0, OU process; Fig. 2A , bottom). On average, 83% of genes (range: 78% -87%; FDR < 0.05) were under stabilizing selection ( Fig. 2A, bottom, fig. S5 ). Nevertheless, the expression of hundreds of genes within each tissue appeared to be neutrally evolving ( Fig. 2A,   top, fig. S5 ). Comparing across tissues and considering only genes robustly expressed over 5 transcripts per million (TPM), 57% (5,669/8,913) of all genes were under stabilizing selection in all tissues in which they were expressed, 39% (2,722) were under stabilizing selection in only some of the tissues where they were expressed, and only 6% (521) were not under stabilizing selection in any of the tissues in our study ( Fig. 2B) .
We assessed the sensitivity and specificity of our detection of genes under expression-stabilizing selection using a jackknifing procedure, where we subsampled to consider phylogenies ranging from 3 to 16 species (SOM). As expected, the number of genes called under stabilizing selection (i.e., rejecting the null hypothesis) increases as more species are included ( fig. S6A ), but does saturate at 14 species. Importantly, the false positive rate (relative to analysis of the full dataset) is very low: less than 1% of genes found as under selection with a subsampled phylogeny are found to be neutral (i.e., accepting the null hypothesis) with the full phylogeny ( fig. S6B ). The OU model's 'evolutionary variance' is highly robust to subsampling, as determined by the very low mean squared error (MSE < 0.005) when estimating variance from subsampled phylogenies.
Indeed, with less than 6 species, the evolutionary variance is far more robust than the simple sample variance used by non-phylogenetic methods ( fig. S6C ). Note that lowly expressed genes (< 5 TPM) had very high evolutionary variance ( fig. S7) , likely due to technical noise (40) , and were thus excluded from all subsequent analyses, resulting an median of 5,860 analyzed genes per tissue.
The OU model's evolutionary variance quantifies the extent of evolutionary constraint on a gene's expression in each tissue, reflecting distinctions between tissues, genes and processes.
Brain had the most genes with low variance (most constraint), and testis the least, consistent with previous estimates of rate of expression evolution for those tissues (28, 41) ( Fig. 2C and fig. S8 ).
Variance was highly correlated between somatic tissues (mean Pearson's r = 0.84), and less correlated between somatic tissues and testis (mean Pearson's r = 0.55) ( fig. S9A ). For genes expressed across three or more somatic tissues, expression level across tissues was negatively correlated with variance across the tissues (median Pearson's r = -0.27), though the tissue of highest expression only matched tissue of lowest variance in 34.5% (1,673 / 4,840) of genes ( fig.   S9B ).
Evolutionary variance and function were strongly associated, consistent with previous reports (42): across all tissues, genes with low variance were enriched for housekeeping functions (e.g., RNA binding and splicing, chromatin organization, cell cycle), whereas those with high variance were enriched for extracellular proteins (rank based enrichment test, SOM, FDR < 0.001). Some processes were enriched in genes with low or high variance only in specific tissues ( Fig. 2D , table S2): among the conserved (low variance) processes were synaptic proteins in brain (FDR = 0.011) and Wnt signaling in testis (FDR = 0.014); processes with high variance included contractile fiber part in heart (FDR = 0.005), oxidoreductase activity in kidney (FDR = 6.10*10 -6 ), and lipid metabolism in liver (2.31*10 -9 ).
There was only a modest correlation between expression and sequence conservation (Pearson's r = -0.25) ( Fig. 2E, SOM) . Genes conserved in both expression and sequence were significantly enriched for housekeeping processes (FDR < 10 -4 , Fig. 2E, table S3 ), and genes divergent in both were enriched for immune and inflammatory response (FDR < 10 -6 , Fig. 2E, table S3 ).
More intriguingly, genes conserved in sequence but divergent in expression were enriched in transcriptional regulators (FDR = 3.1*10 -5 ), especially those involved in embryonic morphogenesis (FDR = 9.8*10 -8 ; e.g., IRX5, HAND2, NOTCH1). Although higher variance may be impacted by environment, changes in cell type composition, and genetic differences, our analysis supports the hypothesis that divergence in gene regulation without protein sequence divergence can account for species-specific phenotypes.
In analysis of rare diseases, sequence conservation is commonly used to prioritize mutations in genes that are more essential and likely causal for rare diseases when mutated (43) (44) (45) . By analogy, we hypothesized that expression conservation should also be predictive of gene essentiality. Indeed, genes that are either essential in culture (46) , essential in mice (47) , or haploinsufficient in humans (48) had significantly lower evolutionary variance (higher constraint) than their non-essential or haplosufficient counterparts across almost all tissues (Wilcoxon rank-sum test p-value < 0.01, Fig. 3A) . Moreover, disease genes with tissue-specific expression (> 5 TPM in three or fewer tissues) consistently exhibited significantly lower variance in the disease-relevant tissue than tissue-specific non-disease genes in each of three tested settings: rare single genes directly linked to non-syndromic autism spectrum disorder (ASD) (brain) (49) , congenital heart defects (heart) (50, 51) , and neuromuscular disease (skeletal muscle) (52) (p-value < 0.05, Fig. 3B ). In ASD-linked genes (but not the other two conditions), we also observed significantly lower variance of ubiquitously expressed disease vs. non-disease genes, perhaps related to observed high rates of co-morbidities with ASD (53).
Next, we hypothesized that the parameters of the OU model can predict disease genes, by highlighting outlier, likely pathogenic, gene expression patterns in rare disease patient data by comparing patient expression to each gene's optimal OU distributions ( Fig. 3C) . This is analogous to causal disease gene discovery by identifying putatively pathogenic sequence mutations in whole exome sequencing (54) (55) (56) (57) . To this end, we obtained RNA-seq of muscle biopsies of 93 patients clinically diagnosed with neuromuscular disease (SOM, table S4). For each patient sample, we calculated a z-score for each gene to assess how they deviate from the (optimal) evolutionary fit for that gene's expression in skeletal muscle, with correction for multiple hypothesis testing ( Fig. 3C, SOM) . Compared to GTEx muscle samples from 184 healthy people (58) , patients had, on average, 3.2-fold more dysregulated genes overall by this measure (Wilcoxon rank sum test p-value =2*10 -9 , Fig. 3D , left), 3.0-fold more dysregulated muscle-expressed disease genes (59) (p-value = 2.1*10 -10 , Fig. 3D , middle), and 2.0-fold more dysregulated known neuromuscular disease genes (p-value = 2.7*10 -4 , Fig. 3D , right). This suggests that the evolutionary parameters fit by the OU model can be used to detect outlier expression values that are more likely to be deleterious. Importantly, in contrast to methods for differential expression between patient and healthy controls, the test does not require a control population, and can be conducted for a single patient sample.
We then tested whether the OU model could be used to identify the causative gene in rare disease analysis. As a proof of principle, we focused on the subset of 8 patients from the muscle disease cohort who were clinically diagnosed with either Becker or Duchenne muscular dystrophy, including confirmation of absent or decreased dystrophin protein via immunoblotting (52) . To compare our approach to a standard differential expression analysis, we ranked genes by outlier expression with z-scores defined based either on (1) comparison to the mean and variance estimated from our evolutionary data; or (2) comparison to a mean and variance estimated from only healthy GTEx human data (Fig. 3E) . By our evolutionary data, fewer genes ranked as significant outliers in each patient (median: 4, range: 0 -32), and the DMD gene ranked as either the top or second most significantly aberrantly expressed gene in 6 of 8 patients, each showing significant underexpression (FDR < 10 -3 ) ( Fig. 3F) . By comparison, scoring in reference to GTEx expression data did not yield such specific results: a median of 14.5 genes were outliers (range: 0 -250), only 4 of 8 patients were called as significantly underexpressing DMD (FDR < 10 -3 ), and its significance in these patients ranked between 1 and 50. Thus, using the OU model's estimate of evolutionary mean and variance of optimal gene expression helps detect gene dysregulation of the actual disease gene and could aid novel disease gene discovery in individual patients, even without any control samples.
Finally, we applied an extension of the OU model (39) to detect directional selection in gene expression. To enrich for changes that are likely to have resulted from ancestral genetic changes, rather than environmental causes, we focused on detecting shifts in expression consistent in direction and magnitude across entire subclades of two or more mammals. We used an extension of the OU model with multiple selection regimes across a single phylogeny (39) , by determining the distribution of expression level as a multivariate normal distribution whose mean and variance are estimated for each (predefined) subclade ( Fig. 4A) . We then identified "differential gene expression" across the tree, in the following way: We applied the extended model for each gene in each tissue and tested each of four alternative hypotheses: OU all , which models a single optimum for all species, and OU primates , OU rodents , OU carnivores , each modeling two optima, one for the ancestral distribution and one for the distribution within primates (branch length = 0.12), rodents (branch length = 0.18), or carnivores (branch length = 0.20), respectively (Fig. 4B) . For each gene, we first used a likelihood ratio test between each OU model and the null hypothesis of a Brownian motion model and removed any models against which the null model could not be rejected. We then assigned the best OU model using goodness-of-fit tests (only when both Akaike and a Bayesian information criterion scores agreed on the best fitting model, SOM).
Finally, as a conservative measure, we retained only those genes that also changed at least 2-fold between subclades and had a mean expression level of at least 5 TPM in one of the subclades.
Within each somatic tissue, we found about 26% of expressed genes to be lineage-specific, while strikingly, in testis, we found almost half (48%) of expressed genes appeared to have lineagespecific differential expression. However, when we used a control analysis with shuffled species assignments to estimate false discovery rates (SOM), we found that we achieved FDR < 30% in only liver (all three clades) and testis (two of three), as well as in the primate clade for brain and lung ( fig. S10) . As an example, in liver, we identified 640, 794, and 615 genes with lineagespecific expression changes in primates, rodents, and carnivores, respectively, highlighting specific metabolic processes diverging in regulation in each clade. The lineage-specific genes deviated significantly from expectation only if there was no clade-specific selection (Fig. 4C) .
Testing for functional enrichment among lineage-specific genes (table S5), we found primatespecific downregulation of genes related to a number of lipid metabolic processes in the liver (FDR = 1.88*10 -11 ). These processes include peroxisomal functions (FDR = 2.45*10 -8 ), fatty acid metabolism (FDR = 1.52*10 -8 ), and lipid transport (FDR = 3.36*10 -3 ) (Fig. 4D, table S5) , and include known regulators of lipid metabolism such as the LDL receptor (LDLR) (60), hepatic lipase (LIPC) (61) , and the transcription factor PPAR-alpha (62) . Thus, the expression of multiple pathways may have diverged at the ancestral primate branch, consistent with observations that human lipidemia is not well-modeled by mice without further genetic modification (63). In another example, genes involved in regulation of immune response were downregulated across rodent livers (FDR = 6.97*10 -4 ), and in testis, microtubule-based movement genes (FDR = 2.82*10 -3 ) and spermatogenesis (FDR = 2.82*10 -2 ) were downregulated across primates (Fig. 4D) , reflecting the known rapid evolution of immune- (42, 64, 65) and reproduction-related genes (66, 67) .
In conclusion, by combining a large dataset of comparative gene expression profiles across mammals with systematic analysis, we showed that gene expression of one-to-one mammalian orthologs is evolving nonlinearly across evolutionary time and is accurately modeled by an OU process. We then show how to use this model to answer three key questions: (1) testing individual gene level for selective regimes, including purifying selection and extent of constraint,
(2) identifying deleterious gene expression in single patient disease tissue by characterizing outliers relative to a predicted distribution of optimal expression for each gene, and (3) detecting lineage-specific expression using an extension that accounts for multiple distributions of optimal expression. Looking forward, we anticipate that the OU model can be further developed for other biological queries, for example by incorporating the contribution of within-species expression variation (68) or testing for stabilizing selection across pathways of genes or paralog families. As shown by our analysis, characterizations of expression across additional tissue types and species under varied developmental and environmental contexts will provide increased power and further insight into the evolution of gene expression, and the relationship between genotype and phenotype.
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Data collection
The following table summarizes the sources for all data used in this study. For a more detailed table of SRA accession numbers and read alignment statistics, see Table S1 . 
Genome and transcriptome annotations
All genomes were downloaded from the UCSC Genome Browser (71) . To assembl transcriptomes, Ensembl gene annotations (35) were downloaded from UCSC Table Browser (table ensGene) and converted to sequence using BEDTools (72) . Ortholog annotations were downloaded from Ensembl BioMart (Ensembl Genes 90) (73) . Only genes that met the following criteria were used for this study: (1) no duplications in any of the studied mammals, (2) an ortholog present in either armadillo or opossum (i.e. placental mammal or marsupial outgroup),
(3) no more than 3 deletions across primates (human, chimp, gorilla, orangutan, macaque, marmoset), (4) no more than 1 deletion across glires (mouse, rat, rabbit), and (5) no more than 1 deletion across laurasiatherians (cow, dog, ferret).
Phylogenetic tree
The phylogenetic tree of vertebrate species was downloaded from UCSC Genome Browser at http://hgdownload.cse.ucsc.edu/goldenpath/hg19/multiz100way/ (71) . Distances between mammals used in this study were extracted using the Environment for Tree Exploration Toolkit (74) .
Alignment and expression quantification
RSEM v1.2.12 (75) was used to align reads to the transcriptome of each species and to quantify transcripts per million (TPM) of each gene using default parameters.
Modelling expression evolution
Quantifying expression difference
To calculate pairwise expression differences between each species ("comparing species") and a reference species (e.g., human in Fig. 1, or mouse in fig. S3 ), we applied principal component analysis (PCA) on pairwise gene expression levels (log 10 (TPM)), considering only genes that were expressed (> 0 TPM) in at least one species. For replicated samples (of the same tissue and species), we used the mean expression across replicates. For each tissue and each pair of species, we used the first principal component as the best fit line between the two species' expression profiles. We then defined the pairwise expression difference as the orthogonal distance from the observed expression level in the comparing species to the best fit line. We used PCA rather than a linear regression because PCA accounts for noise in expression values from both species, while the linear regression would only model noise in the comparing species and treat the reference species as an independent variable.
Fitting linear and nonlinear regression models to mean squared expression distances
Under an Ornstein Uhlenbeck model, the expected mean squared distance across time follows a power law relationship (y = ax k ). To fit this relationship between our observed mean squared expression distances (y) and evolutionary time (x), we log-transformed both axis to relate the variables linearly: log(y) = log(a) + klog(x). We then used basic least squares regression to find coefficients a and k.
For genes whose expression evolution fit better under a Brownian motion model (see below), we simpy used basic least squares regression to find the best fit line between mean squared expression distances and evolutionary time.
Fitting Ornstein-Uhlenbeck (OU) process parameters
Gene expression values (log 10 (TPM)) were first normalized within each tissue to human expression using TMM normalization (76) from the Bioconductor package edgeR (77) .
Brownian motion (BM) and Ornstein-Uhlenbeck (OU) models were fit to expression values using the R package ouch (39) with default parameters. P-values for each gene were calculated using a likelihood ratio test comparing the OU (alternative hypothesis) to the BM (null hypothesis) model, and then corrected for multiple hypothesis testing using the Benjamini-Hochberg false discovery rate (FDR) procedure (78) .
Jackknifing procedure for estimating robustness of OU process parameters
To test the robustness of the OU model, we used a jackknifing procedure where we subsampled phylogenies ranging from 3 to 16 species (out of a total of 17 species). For each phylogeny size, we created ten randomly subsampled phylogenies. We then fit the OU model as described above.
Measuring sequence conservation
Sequence conservation of a gene was defined by mean phyloP score (3) across the coding region of the longest annotated transcript of that gene.
Gene ontology (GO) enrichment analysis
Relationship with evolutionary variance
To test for enriched GO categories across genes with low or high evolutionary variance, we used the ranked enrichment test from GOrilla (79) . To avoid biases due to relationship between lowly expressed genes and high evolutionary variance estimates, we only used genes expressed at > 5 TPM.
Relationship with evolutionary variance and sequence conservation
We tested for enriched GO categories across genes in all four categories of high or low evolutionary variance and high or low sequence conservation. For each tissue separately, we defined "high" or "low" based on the median evolutionary expression variance and median phyloP score, respectively, and assigned all genes expressed at > 5 TPM to one of four categories. For GO enrichment analysis, where only sets with relatively large numbers of genes are typically enriched at levels that survive multiple hypothesis testing correction, we first unified the genes of each category across all tissues and then used GOrilla (79) to test for enrichments in the combined gene lists. Because gene function is related to evolutionary variance, for the background set we used the appropriate list of all high or low expression variance genes expressed at > 5 TPM.
Essential, haploinsufficient, and disease gene sets
The following gene lists were downloaded from the McArthur Lab gene lists repository at https://github.com/macarthur-lab/gene_lists: essential in culture, essential in mice, ClinGen haploinsufficient genes, Genes with any disease association reported in ClinVar, and neuromusclar disease genes. estimated from the evolutionary data. Z-scores were only calculated for genes that were assessed to fit better under the OU rather than the BM model (FDR < 0.05, see Fitting Ornstein-Uhlenbeck process parameters) and whose asymptotic mean was estimated to be 5 TPM or higher. Z-scores were converted to p-values and then corrected for multiple hypothesis testing using the Benjamini-Hochberg FDR procedure (78) . We used a FDR threshold of 0.01 to initially define significance. Of those, we removed another 330 genes that scored as a significant outlier in more than 25% of the GTEx samples.
As a comparator (Fig. 3E, F) , z-scores were also calculated using the sample mean and variance estimated from health human GTEx samples. To ensure comparability between the two methods, we only calculated z-scores for genes that were not filtered out at any steps during the evolutionary method above.
Detecting lineage-specific expression programs
Within each tissue, OU parameters for all four hypotheses (OU all , OU primates , OU rodents , OU carnivores ) were estimated for each gene as described above. Models in which unrealistic parameters were estimated (optimal expression θ > 10 4.5 or θ < 0) were removed. P-values were calculated using a likelihood ratio test comparing each of the OU models to the BM model. Results from each of the four hypotheses were then independently adjusted for multiple hypothesis testing using the Benjamini-Hochberg FDR procedure (78) . For each gene, Akaike and Bayesian information criterion scores were calculated on all models that were significant against the null to determine the best fitting model. A gene was assigned to a best-fitting OU model only when both scores were in agreement. For additional stringency, we only defined genes as being differentially expressed if the fold change between the estimated means across the lineages (e.g., primate mean vs. ancestral mean) was greater than 2-fold and if the mean reached at least 5 TPM in one of the lineages. To estimate the FDR, we performed the same procedure in each tissue using shuffled species assignments (on the same tree topology) and only retained hypotheses that achieved a FDR < 0.30. We performed GO enrichment analysis on each set of up-and down-regulated genes separately, using a background set of genes with mean expression of at least 1 TPM across all species in the appropriate tissue. Dendrograms from hierarchical clustering of gene expression (log 10 (TPM)) within each of seven tissue type (label, top) using Pearson's correlation as the distance metric. See Table S1 for detailed information about each sample. 
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